The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The epidemiology of inhibitors in haemophilia A: a systematic review
Abstract
Summary. This paper emphasizes the importance of distinguishing between the prevalence, incidence and cumulative incidence of inhibitors in haemophilia A. Incidence and cumulative incidence data will include patients with transient inhibitors or whose inhibitors have been eliminated by treatment. As these will not be included in prevalence data, prevalence studies will tend to give rise to lower figures than incidence studies. As a result, the most accurate estimates of the true risk of inhibitor development comes from prospective studies of newly diagnosed haemophiliacs who are tested regularly for the presence of inhibitors. This paper reports a systematic review of the best available evidence relating to the epidemiology of inhibitors in haemophilia A. Cohort studies, registry data reporting incidence or prevalence of inhibitors in patients with haemophilia A, and prospective studies of factor VIII (FVIII) in the treatment of previously untreated patients which reported the development of inhibitors as an outcome, were included in the review. The overall prevalence of inhibitors in unselected haemophiliac populations was found to be 5–7%. The cumulative risk of inhibitor development varied (0–39%). Incidence and prevalence were substantially higher in patients with severe haemophilia. Studies of patients using a single plasma‐derived FVIII (pdFVIII) preparation reported lower inhibitor incidence than those using multiple pdFVIII preparations or single recombinant FVIII preparations. Incidence data should be used to estimate the likely demand for treatments aimed at eliminating inhibitors, whereas the best estimates of the overall burden to the National Health Service (NHS) of treating bleeding episodes in patients with continuing inhibitors will come from prevalence studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
Ehrenforth, S., Kreuz, W., Linde, R., Funk, M., Güngor, T., Krackhardt, B., Kornhuber, B., & Scharrer, I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90874-3 · Cited by 605
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Gl, B., Gomperts, E. D., Courter, S. G., Gruppo, R. A., Em, G., Manco‐Johnson, M. J., Shapiro, A. D., Scheibel, E., White, G. C., & Lee, M. (1994) · PubMed · doi:10.1182/blood.v83.9.2428.bloodjournal8392428 · Cited by 346
Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation
Schwaab, R., Brackmann, H.-H., Meyer, C., Seehafer, J., Kirchgesser, M., Haack, A., Olek, K., Tuddenham, E. G. D., & Oldenburg, J. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649954 · Cited by 331
Astermark, J., Berntorp, E., White, G. C., Kroner, B. L., & THE MIBS STUDY GROUP (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00510.x · Cited by 207
Mortality and causes of death in Dutch haemophiliacs, 1973–86
Rosendaal, F. R., Varekamp, I., Smit, C., Bröcker‐Vriends, A. H. J. T., Van Dijck, H., Vandenbroucke, J. P., Hermans, J., Suurmeijer, T. P. B. M., & Briët, E. (1989) · British Journal of Haematology · doi:10.1111/j.1365-2141.1989.tb06277.x · Cited by 205
Scharrer, Bray, & Neutzling (1999) · Haemophilia · doi:10.1046/j.1365-2516.1999.00300.x · Cited by 200
Oldenburg, J., Picard, J. K., Schwaab, R., Brackmann, H. H., Tuddenham, E. G. D., & Simpson, E. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655945 · Cited by 197
Rosendaal, F., Nieuwenhuis, H., van den Berg, H., Heijboer, H., Mauser- Bunschoten, E., van der Meer, J., Smit, C., Strengers, P., & Briet, E. (1993) · Blood · doi:10.1182/blood.v81.8.2180.2180 · Cited by 194
Hay, C. R. M., Oilier, W., Pepper, L., Cumming, A., Keeney, S., Goodeve, A. C., Colvin, B. T., Hill, F. G. H., Preston, F. E., Peake, I. R., et al. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655944 · Cited by 190
Peerlinck, K., Arnout, J., Gilles, J. G., Saint-Remy, J.-M., & Vermylen, J. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651565 · Cited by 181
LUSHER, J. M., ARKIN, S., ABILGAARD, C. F., & SCHWARTZ, R. S. (1993) · Survey of Anesthesiology · doi:10.1097/00132586-199310000-00058 · Cited by 181
McMillan, C., Shapiro, S., Whitehurst, D., Hoyer, L., Rao, A., & Lazerson, J. (1988) · Blood · doi:10.1182/blood.v71.2.344.344 · Cited by 169
Peerlinck, K., Arnout, J., Di Giambattista, M., Gilles, J. G., Laub, R., Jacquemin, M., Saint-Remy, J. M. R., & Vermylen, J. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655911 · Cited by 161
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
Addiego, J., Kasper, C., Abildgaard, C., Hilgartner, M., Lusher, J., Glader, B., & Aledort, L. (1993) · The Lancet · doi:10.1016/0140-6736(93)91593-b · Cited by 161
Rizza, C. R., & Spooner, R. J. D. (1983) · BMJ · doi:10.1136/bmj.286.6369.929 · Cited by 136
Prevalence of Inhibitors in a Population of 3435 Hemophilia Patients in France
Sultan, Y., & French Hemophilia Study Group (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648507 · Cited by 135
White, G. C., Courter, S. G., Bray, G. L., Lee, M., & Gomperts, E. D. (1997) · PubMed · Cited by 123
Inhibitors occur more frequently in African–American and Latino Haemophiliacs
Aledort, & Dimichele (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.0146c.x · Cited by 122
White, G. C., Courter, S. G., Bray, G. L., Lee, M., Gomperts, E. D., & The Recombinate Previously Treated Patient Study Group (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656030 · Cited by 116
Biggs, R. (1974) · British Journal of Haematology · doi:10.1111/j.1365-2141.1974.tb00476.x · Cited by 107
The natural history of factor VIII inhibitors in patients with hemophilia A.
Gill, F. (1984) · PubMed · Cited by 85
Schwarzinger, I., Pabinger, I., Korninger, C., Haschke, F., Kundi, M., Niessner, H., & Lechner, K. (1987) · American Journal of Hematology · doi:10.1002/ajh.2830240303 · Cited by 74
Giles, A. R., Rivard, G., Teitel, J. M., & Walker, I. (1998) · Transfusion Science · doi:10.1016/s0955-3886(98)00024-1 · Cited by 73
Addiego, J. E., Gomperts, E. D., Shu-Len, L., Bailey, P., Courter, S. G., Lee, M. L., Neslund, G., Kingdon, H. S., & GRIFFITH, M. J. (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648373 · Cited by 71
Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome
Rasi, V., & Ikkala, E. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb06370.x · Cited by 62
Aygören‐Pürsün, E., Scharrer, I., & German Kogenate Study Group (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1665410 · Cited by 58
Development of inhibitors in patients with haemophilia from India
Ghosh, K., Shetty, S., Kulkarni, B. P., Nair, S. B., Pawar, A., Khare, A., Baindur, S., & Mohanty, D. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00505.x · Cited by 53
Aygören‐Pürsün, E., & Scharrer, I. (1997) · PubMed · Cited by 53
Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97
Yee, T. T., Pasi, J., Lilley, P., & Lee, C. A. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01268.x · Cited by 46
Peerlinck, K., Rosendaal, F. R., & Vermylen, J. (1993) · Blood · doi:10.1182/blood.v81.12.3332.3332 · Cited by 46
High Titer Inhibitors in Severe Haemophilia A
Briët, E., Rosendaal, F. R., Kreuz, W., Rasi, V., Peerlinck, K., Vermylen, J., Ljung, R. C. R., Rocino, A., Addiego, J. E., Lorenzo, J. I. L., et al. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648832 · Cited by 36
The incidence of factor VIII inhibitors in the United Kingdom, 1990‐93
Colvin, B. T., Hay, C. R. M., Hill, F. G. H., & Preston, F. E. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb08435.x · Cited by 29
Mauser‐Bunschoten, E. P., van der Bom, J. G., Bongers, M., Twijnstra, M. A. S., Roosendaal, G., Fischer, K., & van den Berg, H. M. (2001) · Haemophilia · doi:10.1111/j.1365-2516.2001.00513.x · Cited by 26
Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C
Lusher, J. M. (1991) · Annals of Hematology · doi:10.1007/bf01703244 · Cited by 25
Incidence and Course of Inhibitors among Patients with Classic Hemophilia
Kasper, C. K. (1973) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649073 · Cited by 25
Schimpf, K., Schwarz, P. H., & Kunschak, M. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1653818 · Cited by 20
Factor VIII Inhibitors in Patients with Hemophilia A
Ören, H., Yaprak, I., & İrken, G. (1999) · Acta Haematologica · doi:10.1159/000040966 · Cited by 18
Skinner, L. M., Lamers, S. L., Sanders, J. C., Eyster, M. E., Goodenow, M. M., & Katzman, M. (1998) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199810010-00001 · Cited by 18
Elalfy, M. S., Tantawy, A. A. G., Ahmed, M. H., & Abdin, I. A. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00449.x · Cited by 17
Zanon, E., Zerbinati, P., Girolami, B., Bertomoro, A., & Girolami, A. (1999) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199904000-00001 · Cited by 15
Aronis, S., Platokouki, H., Kapsimali, Z., Adamtziki, E., KOLOKITHAS, A., & Mitsika, A. (1995) · Haemophilia · doi:10.1111/j.1365-2516.1995.tb00082.x · Cited by 5
Aznar, Lorenzo, L., Molina, Haya, Querol, F., & DasÍ (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.00139.x · Cited by 3
Cited by
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A. K., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M. C., et al. (2013) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,927
Definitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Gouw, S. C., van der Bom, J. G., & Marijke van den Berg, H. (2007) · Blood · doi:10.1182/blood-2006-11-056291 · Cited by 495
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
Peyvandi, F., Mannucci, P. M., Garagiola, I., El-Beshlawy, A., Elalfy, M., Ramanan, V., Eshghi, P., Hanagavadi, S., Varadarajan, R., Karimi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516437 · Cited by 494
Astermark, J., Donfield, S. M., DiMichele, D. M., Gringeri, A., Gilbert, S. A., Waters, J., Berntorp, E., & for the FENOC Study Group (2007) · Blood · doi:10.1182/blood-2006-04-017988 · Cited by 473
Metadata
- Authors
- Wight, J., & Paisley, S.
- Venue
- Haemophilia
- Publisher
- Wiley
- Published
- 2003-06-26
- Volume
- 9
- Issue
- 4
- Pages
- 418-435
- ISSN
- 1351-8216 (ISSN-L)
- 1365-2516
- OpenAlex
- W2037201482
- Cited by
- 627
- References
- 45
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.